MissionIR Articles
Original content written and distributed as part of our ongoing relationships.
-
VistaGen Therapeutics (VSTA) Awarded $197,000 NIH Grant for Expanded PreclinicalDevelopment of New Drug Candidate for Neuropathic Pain
VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics for Central Nervous System (CNS) and Peripheral Nervous System (PNS) disorders and metabolic diseases using…
-
VistaGen Therapeutics (VSTA) Awarded $3,700,000 NIH Drug Development Grant for LeadEpilepsy Drug Candidate
Burlingame, CA, May 24, 2005 /PRNewswire/ — VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics for Central Nervous System (CNS) disorders and metabolic…
Search Articles
Latest Articles
- Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ): Advancing a Premier North American Copper District
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
- Safe Pro Group Inc. (NASDAQ: SPAI) Advanced AI Patent Protections with Notification Publications in Australia, Israel, and the European Region
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
- MissionIRNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Prices $7 Million Public Offering of Common Stock and Pre-Funded Warrants